Equity Analyst, LightStream Research

Shifara Samsudeen, FCMA, CGMA

A chartered management accountant with more than 10 years of rich experience in investment research and financial analysis. Worked as an equity analyst for one of the world's largest asset managers with USD2.5trn in AUM covering numerous sectors including chemicals, retail, tech, autos, telco, real-estate and banks, globally. Experienced in fundamental equity research, industry research, commodity studies, forensic accounting, and due diligence reviews.

Equity Analyst

SciClone Pharmaceuticals IPO Valuation: Not Pleasing

Cheerwin Group IPO: Doing Its Best to Innovate, Diversify and Grow in a Mature Market

JD Logistics IPO: Expanding External Customer Base Supports Top Line Growth and GPM Expansion

Kuaishou IPO Trading Update: Further Upside Seems Limited; We Are Looking for Exit Points

New Horizon Health IPO Valuation: Healthy Valuation

New Horizon Health IPO: Aiming to Become Pioneer in Cancer Screening

Battle Lines Drawn As BABA Builds Out First/Last-Mile Capacity; But Who Will Fund 75+ Bn CNY CapEx?

Long-Short Analysis on Japan, Asia and the World

LightStream Research

LightStream conducts quantitatively rigorous and data-driven analysis with a focus on Japan and Asia.

We consistently cover the Tech, Consumer and Industrial sectors, and provide ECM and Events coverage more broadly.

We supplement traditional qualitative insights from company relationships with a robust quantitative foundation that examines as much historical data as is available.
We further refine the accuracy of our insights and calls through the use of alternative data to flesh out current trends, and through a valuation framework that emphasises non-superficial peer group selection and a proper attempt to understand the metrics and changes that have driven security valuations in the past.

Equity Capital Markets

New Horizon Health  / Equity Capital Markets

<a href="https://www.smartkarma.com/entities/new-horizon-health-limited" target="_blank" data-smartkarma-citation="entities:31039:1" rel="noopener">New Horizon Health (6606 HK)</a> , the pioneer in China’s colorectal cancer screening market started trading on the Hong Stock Exchange on 18th February. The company set its final IPO pricing at HK$26.66 per share, the upper end of the IPO price range of HK$22.66-26.66 per share and raised net proceeds of HK$2.04bn (approx. US$263m).NHH’s shares opened strong at its debut at HK$76 per share, about 185% higher than the final IPO pricing of HK$26.66 per share. The company’s IPO was oversubscribed by more than 4,000 times, making it the second most oversubscribed stock in the history of HKEX.The company’s shares closed at HK$84 per share at the end of its first day of trading, a lofty premium of 215% to the final IPO price.

New Horizon Health (6606 HK) , the pioneer in China’s colorectal cancer screening market started trading on the Hong Stock Exchange on 18th February. The company set its final IPO pricing at HK$26.66 per share, the upper end of the IPO price range of HK$22.66-26.66 per share and raised net proceeds of HK$2.04bn (approx. US$263m).NHH’s shares opened strong at its debut at HK$76 per share, about 185% higher than the final IPO pricing of HK$26.66 per share. The company’s IPO was oversubscribed by more than 4,000 times, making it the second most oversubscribed stock in the history of HKEX.The company’s shares closed at HK$84 per share at the end of its first day of trading, a lofty premium of 215% to the final IPO price.

New Horizon Health IPO Trading Update: A Blockbuster IPO but It’s Time You Plan an Exit Strategy